Enzo Biochem (NYSE:ENZ) Shares Pass Above 200 Day Moving Average of $1.13

Enzo Biochem, Inc. (NYSE:ENZ)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.13 and traded as high as $1.13. Enzo Biochem shares last traded at $1.12, with a volume of 59,045 shares traded.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Enzo Biochem in a research report on Saturday. They set a “hold” rating on the stock.

Enzo Biochem Stock Down 0.9 %

The firm’s 50-day moving average price is $1.12 and its 200 day moving average price is $1.13.

Hedge Funds Weigh In On Enzo Biochem

Several hedge funds and other institutional investors have recently modified their holdings of ENZ. Wittenberg Investment Management Inc. acquired a new position in Enzo Biochem during the fourth quarter worth about $95,000. Renaissance Technologies LLC grew its holdings in shares of Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the last quarter. Finally, XTX Topco Ltd increased its position in Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares in the last quarter. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.